{
    "root": "676907d3-b374-4baa-8422-c04706409540",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Ivabradine"
    },
    "value": "20250428",
    "ingredients": [
        {
            "name": "IVABRADINE HYDROCHLORIDE",
            "code": "TP19837BZK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MALTODEXTRIN",
            "code": "7CVR7L4A2D"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "ivabradine tablets hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated : reduce risk hospitalization worsening heart failure adult patients stable , symptomatic chronic heart failure reduced left ventricular ejection fraction . ( 1.1 )",
    "contraindications": "adult patients starting dose 2.5 ( vulnerable adults ) 5 mg twice daily food . 2 weeks treatment , adjust dose based heart rate . maximum dose 7.5 mg twice daily . ( 2.1 )",
    "warningsAndPrecautions": "tablets : ivabradine 5 mg tablets formulated orange colored , capsule shaped , film-coated tablets , functionally scored debossing `` `` & `` `` one side `` 2 `` side . supplied follows : • bottles 60 tablets child-resistant closure ( ndc 72205-336-60 ) • bottles 180 tablets child-resistant closure ( ndc 72205-336-18 ) ivabradine 7.5 mg tablets formulated orange colored , round shaped , film-coated tablets debossed “ myocardial infarction ” one side “ 1 ” side . supplied follows : • bottles 60 tablets child-resistant closure ( ndc 72205-337-60 ) • bottles 180 tablets child-resistant closure ( ndc 72205-337-18 ) storage store 25°c ( 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "ivabradine contraindicated patients : • acute decompensated heart failure • clinically significant hypotension • sick sinus syndrome , sinoatrial block 3rd degree av block , unless functioning demand pacemaker present • clinically significant bradycardia [ ( 5.3 ) ] • severe hepatic impairment [ ( 8.6 ) ] • pacemaker dependence ( heart rate maintained exclusively pacemaker ) [ ( 7.3 ) ] • concomitant strong cytochrome p450 3a4 ( cyp3a4 ) inhibitors [ ( 7.1 ) ]",
    "indications_original": "Ivabradine tablets are a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 )",
    "contraindications_original": "Adult patients Starting dose is 2.5 (vulnerable adults) or 5 mg twice daily with food. After 2 weeks of treatment, adjust dose based on heart rate. The maximum dose is 7.5 mg twice daily. ( 2.1 )",
    "warningsAndPrecautions_original": "Tablets:\n                      Ivabradine 5 mg tablets are formulated as orange colored, capsule shaped, film-coated tablets , functionally scored with debossing \"M\" & \"I\" on one side and \"2\" on other side. They are supplied as follows: • Bottles of 60 tablets with child-resistant closure (NDC 72205-336-60) • Bottles of 180 tablets with child-resistant closure (NDC 72205-336-18) Ivabradine 7.5 mg tablets are formulated as orange colored, round shaped, film-coated tablets debossed with “MI” on one side and “1” on the other side. They are supplied as follows: • Bottles of 60 tablets with child-resistant closure (NDC 72205-337-60) • Bottles of 180 tablets with child-resistant closure (NDC 72205-337-18)\n                     \n                        Storage\n                     \n                      Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Ivabradine is contraindicated in patients with:  • Acute decompensated heart failure  • Clinically significant hypotension  • Sick sinus syndrome, sinoatrial block or 3rd degree AV block, unless a functioning demand pacemaker is present  • Clinically significant bradycardia  [see Warnings and Precautions (5.3)]\n                      • Severe hepatic impairment [see Use in Specific Populations (8.6)]\n                      • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions (7.3)] \n                      • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions (7.1)]"
}